Introduction: While the molecular epidemiology of extended-spectrum--lactamase (ESBL)-producing E. coli is well known in Europe due to effective surveillance networks and substantial literature, data for Africa are less available, especially in Djibouti. Methodology: We studied 31 isolates of ESBL-producing E. coli from Djibouti and compared these molecular results with data available in Africa. Results: Susceptibility rates were 3.2% for ceftazidim, 48.4% for piperacillin-tazobactam, 90.3% for amikacine and 16.1% for ofloxacin. No isolate showed resistance to carbapenems or colistin. 30 E. coli (96.8%) were positive to blaCTX-M-15, 1 (3.2%) to blaCTX-M-14 and 10 (32.3%) to narrow-broad-spectrum blaTEM. No blaSHV were detected. Fluoroquinolone resistance analysis showed that 30 ofloxacin-resistant E. coli had the mutation Ser-83->Leu on the gyrA gene. 24 E. coli (77.4%) harboured the plasmid-borne aac(6 ')-Ib-cr gene. No E. coli carried the genes qnrA, qnrB and qepA. 10 isolates (32.3%) belonging to the ST131 clone. The plasmid incompatibility group most widely represented in our collection was IncFIA/IB/II. Conclusions: There is no major difference with African epidemiology. In particular, we notice the international diffusion of specific clonal group ST131.
Introduction
Escherichia coli (E. coli), a Gram-negative bacillus belonging to the Enterobacterales family, colonizes the digestive tract and can cause infection, especially of the urinary, intestinal or neonatal varieties. It is the primary agent of bacteraemia and urinary tract infections in Europe [1] . In Africa, E. coli is the second-most prevalent Enterobacterales responsible for communityacquired bacteraemia and one of the main agents of diarrhea, causing more than 10% of deaths in children under 5 years [2, 3] . Antibiotic resistance in E. coli has steadily increased over the years, leading to the emergence and the international spread of multidrugresistant Enterobacterales. This phenomenon is linked to a growing selection pressure for antibiotics, sometimes associated with misuse, interpersonal transmission, and a significant contribution of the environment and animal feed. While the molecular epidemiology of extended-spectrum--lactamase (ESBL)-producing E. coli is well known in Europe due to effective surveillance networks and substantial literature, data for Africa are less available, often being limited to the Northern part of the continent. Despite the importance of the problem and its consequences on health and economic measures, few countries in Africa have national surveillance and control programmes against resistance, as recommended by the World Health Organization [4] . During his tenure, a biologist colleague, working at the laboratory of the military hospital Bouffard, reported an increase of thirdgeneration cephalosporin-resistant Enterobacterales (6% in 2009 to 24% in 2014 on isolates from clinical samples; unpublished data). Consequently, we decided to establish a genetic resistance profile of ESBLproducing E. coli isolates collected before the closure of the military hospital Bouffard in Djibouti and to compare these molecular results with other data available in Africa.
Methodology

Bacterial isolates and setting
Thirty-one strains of ESBL-producing E. coli isolated from 31 different patients were collected in 2015 at the military hospital Bouffard in Djibouti.
These isolates were obtained from clinical specimens such as urine (12 samples) , blood cultures (2 samples), bronchoalveolar fluids (2 samples), pus (5 samples) and from rectal swabs (10 samples for screening purposes). Of these 31 isolates, 20 (64.5%) were isolated from men and 11 (35.5%) from women. Of the patient base, 20 (64.5%) patients were hospitalized, 4 (12.9%) were at the emergency unit and 7 (22.6%) had medical consultation in hospital. Regarding military service status, 29 (93.5%) patients were native or Djiboutian soldiers, 2 (6.4%) were French servicemen.
Isolates were sent to our laboratory in France for further phenotypic and molecular investigation: E. coli identification performed in Djibouti was confirmed by a matrix-assisted laser desorption ionization-time of flight mass spectrometry system in France (MALDI-TOF, Microflex ® , Bruker Daltonics, GmbH, Bremen, Germany).
Susceptibility testing
Antimicrobial susceptibility was determined by the disc diffusion method on Mueller Hinton agar plates (Biorad, Marnes-la-coquette, France). Quality control strains were used in particular extended-spectrum βlactamase producing Klebsiella pneumoniae ATCC 700603. The results were interpreted according to the Antibiogram Committee of the French Society of Microbiology 2017. ESBL production was confirmed by double-disc synergy testing. The minimum inhibitory concentration (MIC) of colistin was determined on each isolate in a liquid medium using the UMIC Colistine ® kit (Biocentric, Bandol, France).
Primers, DNA extraction, PCR conditions and sequencing
Primers to target β-lactamases genes encoding TEM; SHV; CTX-M; quinolones resistance genes gyrA, qnrA, qnrB, qnrS, qepA, aac(6')-Ib-cr and aminoglycoside resistance genes armA, rmtA, rmtB were used. The E. coli phylogenetic groups (A, B1, B2 and D) were determined using a PCR-based method according to the presence of the two genes (chuA and yjaA) and an anonymous DNA fragment (TsPE4.C2) [5] . Primers allowing detection of the E. coli O25b-ST131 clone were used according to Clermont et al. [6] . The E. coli isolates were typed by multilocus sequence typing (MLST) by amplifying partial fragments of eight housekeeping genes (dinB, icdA, pabB, polB, putB, trpA, trpB and uidA) following the protocols available at the website: http://bigsdb.pasteur.fr/ecoli/ecoli.html. Plasmid incompatibility was studied according to the work of Compain et al. by several PCRs targeting the relaxase genes of each type of plasmids [7] .
All primers used in this study are listed in Supplementary Table 1 .
Lysis by boiling was used for total DNA extraction as previously described [8] . Simplex PCR was performed in a 50 μL mix with 2U of Taq DNA polymerase, 10XPCR buffer, MgCl 2 (Qiagen, Courtaboeuf, France), 200 μM of each deoxynucleotide triphosphate (dNTP Mix, Eurobio, Courtaboeuf, France), 0.2 pmol/μL of each primer, 40 μL of sterile water and 2 μL of total DNA extract. PCR conditions consisted of an initial activation at 95°C for 5 min, followed by 35 cycles of 95°C for 1 min, 58°C for 40 s and 72°C for 40 s with a final extension at 72°C for 7 min. PCR products were separated with QIAxcel Advanced System (Qiagen, Hilden, Germany). PCR products were purified using the QIAquick PCR purification kit (Qiagen, Hilden, Germany) and subjected to DNA sequencing using BigDye terminator v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA, USA) and an Applied Biosystems 3730 XL capillary sequencer. Sequence analysis was carried out using CEQ 8000 system analysis (Beckman Coulter, Brea, USA).
Results
Of 31 ESBL-producing E. coli analysed no isolate showed resistance to carbapenems (ertapenem). All isolates were susceptible to colistin, with a mean MIC at 0.27 mg/L. Susceptibility rates were 83.9% for cefoxitin, 3.2% for ceftazidim, 48.4% for piperacillintazobactam, 41.9% for temocillin, 90.3% for amikacin, 38.7% for netilmicin, 19.4% for tobramycin, 41.9% for gentamicin, 12.9% for ofloxacin and 19.4% for ciprofloxacin.
PCR testing for β-lactamase genes followed by sequencing revealed 30 E. coli (96.8%) positive to extended spectrum β-lactamases bla CTX-M-15 and 1 (3.2%) to bla CTX-M-14 and 10 (32.3%) to narrowspectrum Ambler class A β-lactamases: 6 (19.4%) to bla TEM-6 , 2 (6.5%) to bla TEM-190, 1 (3.2%) to bla TEM-2, 1 (3.2%) to bla . No bla SHV were detected. Eight E. coli were co-carriers of both TEM and CTX-M.
Fluoroquinolone resistance analysis showed that all the ofloxacin-resistant E. coli (83.9%) had the mutation known and described in the literature on the gyrA gene (QRDR region with mutations at positions 83 (Ser->Leu)) and/or carried a plasmid-borne resistance gene. Two E. coli (6.5%) were positive for the plasmidborne qnrS gene: the both were resistant to ofloxacin, one was resistant to ciprofloxacin, while the other was susceptible. Interestingly, 24 E. coli (77.4%) harboured the plasmid-borne aac(6')-Ib-cr gene: all these bacteria were resistant to ciprofloxacin except for one E. coli (isolate 45) that was susceptible to all quinolones and resistant to gentamicin. No E. coli carried the plasmidmediated quinolone resistance genes qnrA, qnrB and qepA.
Regarding aminoglycoside resistance, armA, rmtA and rmtB PCRs performed on the three amikacin intermediate/resistant E. coli (9.7%) were negative.
Finally, the IncFIA/IB/II, IncI1 and IncB/O/K plasmids were detected respectively in 25 (80.6%), 8 (25.8%) and 1 (3.2%) of the 31 E. coli studied. Five isolates remained non-typable within the 18 major incompatibility groups [7] .
Regarding molecular epidemiology, 12 E. coli belonged to phylogroup B2 (38.7%), 11 to group A (35.5%), 7 to group D (22.6%) and 1 to group B1 (3.2%). ST131 PCR revealed 10 isolates (32.3%) belonging to the ST131 clone. These results were confirmed by sequence analysis using the MLST website. Indeed, the 10 isolates identified ST131 by conventional PCR were typed ST43, one of the 3 major clades of ST131 clones. The other clones identified belonged to 13 different STs: ST2 (19.3%), ST741 (6.4%), ST8 (6.4%) and ST3, 44, 53, 132, 500, 692, 698, 721, 740, 829 (3.2%). One non-ST131-E. coli remained unclassified because of the impossibility to amplify one of its MLST genes despite several assays and conditions.
All results are summarized in Table 1 .
Discussion
We have provided genetic data on molecular epidemiology in ESBL-producing E. coli collected in Djibouti. To our knowledge, this study is the first report of molecular epidemiology in ESBL in this country. A total of 31 isolates of ESBL-producing E. coli recovered from clinical samples and rectal swabs were analysed. Although limited, especially by the small number of isolates, this study allowed three major results to be highlighted.
First, the bla CTX-M-15 gene was the most commonly detected ESBL-encoding gene in our collection, as reported by other works conducted in North America, Europe, and South America [9] . Data from Malawi, Nigeria, and Tanzania are very similar with respectively 95.2%, 85.7%, and 100% of ESBL-producing E.coli belonging to the CTX-M-15 group [3, 9, 10] . This further strengthens the converging data about the high diffusion of this gene, including this phenomenon as reported in the Horn of Africa.
Secondly, genetic explorations showed a high molecular diversity and frequent combinations of antibiotic-resistance plasmids, in particular those encoding beta-lactamases and resistance to fluoroquinolones. The virulent extra-intestinal phylogroup B2 was predominant in our collection, followed by the commensal phylogroup A. These data are consistent with the results of a similar study conducted in Malawi in 2017 in which 34% of E.coli belonged to phylogroup B2 and 23.4% to phylogroup A2 [3] . These groups were also predominant in Tanzania in the study of Mshana et al. In our study, bla CTX-M-15 gene was detected in the 5 different E. coli phylogroups and in 14 different STs. One-third of the CTX-M-15-producing E. coli group belonged to the ST131 clone. This predominance of ST131 despite the genomic diversity of CTX-M-15 has already been described in Tanzania, Asia, Europe, and America [3, 11] . The ST131 is a pandemic clone responsible for the high incidence of extraintestinal pathogenic E. coli and has been known widely for its contribution to the worldwide dissemination of multidrug resistance [12] . The success of this ST has been explained by its acquisition of fluoroquinolone resistance and additional virulence factors [13] . Concerning the genetic support of resistance, the plasmid incompatibility group most widely represented in our collection was IncFIA/IB/II. It is also highlighted in studies carried out in Malawi and Tanzania with respectively 89% and 73% of the E. coli studied [3, 11] . The IncF plasmids groups represent the most prevalent incompatibility type and have been identified worldwide in Enterobacterales from different sources [14] . The IncF plasmids have been reported to be characterized by a low copy number with a size >100kb and having more than one replicon to promote the initiation of replication. The multi-replicon status has been described by Villa et al. to be one means by which plasmids with a narrow host range can accomplish broad host range replication [15] . The IncF plasmids possess great versatility of intracellular adaptation by the rapid evolution of the regulatory sequences of the replicons which explains why they are widely diffused in Enterobacterales [15] . Various plasmids that differ in incompatibility groups and replicon types have been characterized in E. coli ST131 isolates, but the narrow-host-range IncF is the most common Inc type detected in ST131 E. coli with bla CTX-M genes [16] . Finally, in our collection, quinolone resistance was clearly correlated to mutations observed on the gyrA gene. Chromosomal resistance is therefore, as in Europe, still predominant. However, the plasmid-borne variant aac(6')-Ib-cr was also very common (77.4%). Its prevalence in our study was higher than in other reports in Africa. The variant was evidenced in Egypt, Morocco and Malawi in only 10 to 20% of ESBLproducing E.coli isolates [3, 17, 18] . The cr variant of aac(6′)-Ib encodes an aminoglycoside acetyltransferase that confers reduced susceptibility to ciprofloxacin by N-acetylation of its piperazinyl amine. The presence of aac(6′)-Ib-cr alone increases substantially the frequency of selection of chromosomal mutants upon exposure to ciprofloxacin [19] . Conversely, the qnr and qepA genes were poorly represented in our collection (< 10% for qnr, 0% for qep), as already reported in Algeria, Morocco, and Malawi [3, 18, 20] , whereas their prevalences appeared to be higher in Egypt, ranging from 17 to 23% for qnr and 15% for qep in ESBLproducing E.coli [17] . Plasmids carrying the aac(6′)-Ib-cr variant were associated with different incompatibility groups but mainly with the IncF type [21] . In previous reports, this determinant was carried by a variety of replicons, such as IncFII, IncN, and IncFIA [22, 23] .
Conclusion
In conclusion, we describe a collection of 31 ESBLproducing E. coli isolates in Djibouti. To our knowledge, this is the first available data in this country. There is no major difference in this data when compared with epidemiology in other African countries. In particular, we will note the international diffusion of specific clonal group ST131. The establishment of surveillance networks and the creation of standardized technical and epidemiological protocols are essential to control and prevent the circulation and dissemination of these multi-resistant Enterobacterales. A continuity in the study of the E. coli and others Enterobacterales is essential in order to detect any emergent phenomena (e.g. carbapenemase). Supplementary Table 1 . Primers used in this study.
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